Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares

Saturn V sold 822,007 shares of Dyne Therapeutics in Q1, with the estimated transaction value at $14.17 million based on quarterly average prices. The article is a factual ownership/flow update rather than an operating or earnings development. Impact is likely limited unless accompanied by broader insider selling or other company-specific news.

Analysis

Saturn V sold 822,007 shares of Dyne Therapeutics in Q1, with the estimated transaction value at $14.17 million based on quarterly average prices. The article is a factual ownership/flow update rather than an operating or earnings development. Impact is likely limited unless accompanied by broader insider selling or other company-specific news.